February 4, 2012
| Bio-IT World > Rubin's Risky Business


Rubin's Risky Business



Oct. 16, 2006 | Gerry Rubin's successful partnership with Craig Venter to sequence the Drosophila genome in 1999 was a stunning dress rehearsal for Celera's assembly of the human genome. But for Rubin, it was an end in itself, the culmination of the UC Berkeley geneticist's decade-long dream to sequence the genome of his favorite model fruit fly.

In 2000, seeking a fresh challenge, Rubin joined Nobel laureate Tom Cech as the new leadership team at HHMI, ushering in a new era of "risky" research and encouraging - nee insisting that - the nation's smartest scientists use the institute's lavish resources to conduct bolder, more imaginative lines of research.

But Janelia Farm represents an even bolder vision - a new interdisciplinary research campus modeled on Bell Labs to foster new technologies and areas of research. "We started with the premise that we'd try to do things that aren't done well elsewhere," a relaxed Rubin told me. "There's not been good funding for developing new tools and new methods."

Rubin wanted to avoid high-profile areas such as genomic medicine, where "smart people will get money from the NIH." Instead, HHMI looked for problems that would benefit from an interdisciplinary environment, ideally with a technological component. Following a set of scientific workshops, two major goals/criteria were identified.

Says Rubin: "One was the goal of understanding how information is stored and interpreted in the nervous system. It starts with the premise - which I hold strongly - of evolutionary conservation. We believe that there are fundamental mechanisms underlying how information is processed in all animals and we can discover these mechanisms in genetically tractable organisms, such as fruit flies, mice, worms."

Rubin commends the NIH for pouring money into research on Alzheimer's, Parkinson's, and other neurological disorders, but there is little left for basic research. "This may be medically relevant in 30-40 years," says Rubin. "That's fine, that's soon enough."

The other goal for Janelia Farm is to develop methods and techniques to image neural activity. "NIH spends lots of money on imaging, but its nearly all human diagnostics," Rubin explains. "We want to study the nervous system and improve imaging methods, build better microscopes, and [develop] computational analysis."

As for his own research, Rubin has scoped out his own project "to identify all the enhancers and promoters in the Drosophila genome that are directed to subsets of cells in the adult brain." The project involves making thousands of transgenic animals, using his extensive high-throughput genomics experience. The end result will be a valuable tool for the community.

Misfits and Molecules
What particularly pleases Rubin is the preponderance of physicists arriving at Janelia Farm. "We have more people with physics undergraduate degrees than biology degrees: We have mathematicians, computational scientists, physicists, biologists, they're all beginning to interact."

One of the early arrivers is Gene Myers, former chief of informatics at Celera. "The type of people working at Celera in its heyday are exactly the type of people we want working here," says Rubin. "We wanted to be different. We didn't want to be competitive with Harvard Medical School or the Whitehead Institute.... We wanted to do things here that attract "misfits" - people that don't fit into conventional academic institutions."

Breaking these boundaries is paramount for HHMI's bold experiment to succeed. The research facility contains 147,000 square feet of Belgian glass, one of the largest installations in the US, providing open visibility into every laboratory. Compressed lunch hours encourage communal dining; and there is a pub named "Bob's" after HHMI's resident architect, Bob McGee, which Rubin says serves a "nice cappuccino" and another communal venue in the evenings.

Janelia Farm has its skeptics, but that's fine with Rubin. "Half of people think this is just crazy. Only ten percent people say this is for them, this is where I want to be. My goal going in was for Janelia to be different enough that only ten percent of scientists would be enthusiastic." -- K.D.

Return to main article.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .